医学
荟萃分析
随机对照试验
置信区间
子群分析
静脉血栓形成
系统回顾
血栓形成
外科
梅德林
内科学
政治学
法学
作者
Gaurav Nepal,Sanjeev Kharel,Christopher M. Jones,Megan Ariel Coghlan,Jayant Kumar Yadav,Stella Goeschl,Rajan Lamichhane,Subash Phuyal,Rajeev Ojha,Gentle Sunder Shrestha
标识
DOI:10.1177/11795735221131736
摘要
Cerebral venous thrombosis (CVT) is a rare thrombotic condition which is traditionally treated with anti-coagulation therapy. Subsets of patients with severe CVT have been treated with endovascular thrombectomy (EVT). Despite the high estimated mortality associated with severe CVT, there has been only one randomized control trial done regarding safety and efficacy of EVT in severe CVT compared to standard medical management. Evidence in this area is lacking.The aim of this systematic review is to analyze all existing literature and generate robust information regarding the role of EVT in the management of patients with severe CVT.This systematic review and meta-analysis followed PRISMA guideline. PubMed, Embase, Google Scholar, and CNKI were searched for eligible studies from 2007 to 2021. Safety and efficacy of EVT were evaluated by meta-analyzing recanalization status, the good functional outcome at follow-up, recurrent CVT, new hematoma. A pooled proportion with a 95% confidence interval was derived from a meta-analysis of various outcomes (CI).A total of 33 studies comprising 610 patients treated with EVT were included for analysis which comprised one randomized control trial, one prospective study and 31 retrospective studies. Based on pooled data, 85% of patients had good functional outcome, 62% had complete recanalization, 5% had all-cause mortality, and 3% had catheter related complications. The efficacy outcomes in this analysis had a significant heterogeneity and a subgroup analysis was also done to explain these findings. The minimum time of follow up was 3 months and varied EVT techniques were used across the studies.This meta-analysis suggests EVT may be safe and efficacious in treating patients with severe CVT.Our protocol was registered with PROSPERO: International prospective register of systematic reviews with the registration number CRD42021254760.
科研通智能强力驱动
Strongly Powered by AbleSci AI